Project Grant R44AA025804

The National Institute on Drug Abuse, part of the Department of Health and Human Services, awarded Longieva Therapeutics, Inc. $399,989 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct Phase I SBIR research evaluating the efficacy of a novel cannabinoid receptor 2 agonist against opioid use disorder. Longieva is developing 36040, a cAMP-biased CB2R agonist designed to mitigate opioid dependence by reducing dopaminergic neuron excitability and...

The National Institute on Drug Abuse awarded Praeventix LLC $355,190 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct in vivo characterization of 5-HT7 modulators in rat models of opioid use disorder. The work evaluates the impact of the lead compound PRA078, a novel 5-HT7 antagonist, on dopamine pathways and cognitive flexibility in animal models of opioid dependence. The research addresses therapeutic gaps in opioid use disorder treatment, where...

The National Institute on Drug Abuse awarded the University of Pittsburgh $700,254 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to examine how combined nicotine and opioid exposure alters the prefrontal cortex in opioid use disorder. The research addresses the gap between current OUD treatments and patient outcomes, particularly the role of nicotine dependence as a confounding factor. Between 80–90 percent of individuals with OUD smoke, yet smoking...

The National Institute on Alcohol Abuse and Alcoholism awarded $293,684 to Remedi, Inc. on July 20, 2026, under the Alcohol Research Programs funding mechanism (CFDA 93.273) to develop an oral formulation of dimethyltryptamine (DMT) co-formulated with CX157, a proprietary reversible monoamine oxidase-A inhibitor, for treating alcohol use disorder. Remedi is addressing a critical pharmacokinetic barrier to DMT therapy: rapid degradation by monoamine oxidase when administered orally, which...

The National Institute on Alcohol Abuse and Alcoholism awarded Witii Pharmaceuticals, Inc. $306,149 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to develop a novel once-daily extended-release formulation of acamprosate calcium for alcohol use disorder. The recipient will optimize an extended-release tablet formulation designed to maintain therapeutic drug levels for 18 to 24 hours, replacing the current regimen of twice-daily 333 mg delayed-release tablets taken...

This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...

The National Institute on Drug Abuse awarded The Research Foundation For The State University of New York, doing business as SUNY Downstate Health Sciences University, $6.942 million on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) for a longitudinal study examining neighborhood conditions, neural circuits, and substance use behaviors across the early life course. Performance runs through June 30, 2029, in New York. The project integrates data across...

The National Institute on Drug Abuse awarded Icahn School of Medicine at Mount Sinai $720,691 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to design and develop blood-brain barrier-crossing conjugates that enable delivery of antisense oligonucleotides to the brain for treating cocaine use disorder. The project addresses the lack of FDA-approved medications for cocaine use disorder by leveraging recent advances in antisense oligonucleotide technologies to...

The National Institute on Drug Abuse awarded Psychogenics Inc. $398,947 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical evaluation of two novel molecules as potential pharmacotherapies for cocaine use disorder. Psychogenics will evaluate the compounds' effects in behavioral models of cocaine self-administration and stress-induced reinstatement of drug-seeking behavior. The work includes testing both molecules' ability to reduce cocaine...

The National Institute on Drug Abuse awarded the University of Southern California $149,766 on August 12, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate simultaneous nicotine, alcohol, and cannabis co-use among young adults. The funded research examines patterns of use, subjective experiences, and consequences of simultaneous substance co-use—defined as using multiple substances close in time so their effects overlap—among approximately 3,860 young adults...